Background Obesity-associated inflammation is of critical importance in the development of insulin resistance and non-alcoholic fatty liver disease. Since the cannabinoid receptor CB2 regulates innate immunity, the aim of the present study was to investigate its role in obesity-induced inflammation, insulin resistance and fatty liver. Methodology Murine obesity models included genetically leptin-deficient ob/ob mice and wild type (WT) mice fed a high fat diet (HFD), that were compared to their lean counterparts. Animals were treated with pharmacological modulators of CB2 receptors. Experiments were also performed in mice knock-out for CB2 receptors (Cnr2 ？/？). Principal Findings In both HFD-fed WT mice and ob/ob mice, Cnr2 expression underwent a marked induction in the stromal vascular fraction of epididymal adipose tissue that correlated with increased fat inflammation. Treatment with the CB2 agonist JWH-133 potentiated adipose tissue inflammation in HFD-fed WT mice. Moreover, cultured fat pads isolated from ob/ob mice displayed increased Tnf and Ccl2 expression upon exposure to JWH-133. In keeping, genetic or pharmacological inactivation of CB2 receptors decreased adipose tissue macrophage infiltration associated with obesity, and reduced inductions of Tnf and Ccl2 expressions. In the liver of obese mice, Cnr2 mRNA was only weakly induced, and CB2 receptors moderately contributed to liver inflammation. HFD-induced insulin resistance increased in response to JWH-133 and reduced in Cnr2 ？/？ mice. Finally, HFD-induced hepatic steatosis was enhanced in WT mice treated with JWH-133 and blunted in Cnr2 ？/？ mice. Conclusion/Significance These data unravel a previously unrecognized contribution of CB2 receptors to obesity-associated inflammation, insulin resistance and non-alcoholic fatty liver disease, and suggest that CB2 receptor antagonists may open a new therapeutic approach for the management of obesity-associated metabolic disorders.
References
[1]
Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881–887.
[2]
Haslam DW, James WP (2005) Obesity. Lancet 366: 1197–1209.
[3]
Parekh S, Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 132: 2191–2207.
[4]
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796–1808.
[5]
Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860–867.
[6]
Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169–2180.
[7]
Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821–1830.
[8]
Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, et al. (2007) Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest 117: 2877–2888.
[9]
Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, et al. (2009) Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 58: 125–133.
[10]
Postic C, Girard J (2008) Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118: 829–838.
[11]
Di Marzo V (2008) Targeting the endocannabinoid system:to enhance or reduce? Nature Reviews Drug Discovery 7: 438–455.
[12]
Mallat A, Lotersztajn S (2008) Endocannabinoids and Their Receptors in the Liver. Am J Physiol Gastrointest Liver Physiol 294: G9–G12.
[13]
Pacher P, Batkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389–462.
[14]
Kunos G, Osei-Hyiaman D (2008) Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 294: G1101–1104.
[15]
Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400–411.
[16]
Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature Medicine 434: 782–786.
[17]
Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, et al. (2008) CB2 receptors as new therapeutic targets during liver diseases. Br J Pharmacol 153: 286–289.
[18]
Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, et al. (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. Faseb J 21: 1788–1800.
[19]
Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, et al. (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141–149.
[20]
Even PC, Perrier E, Aucouturier JL, Nicolaidis S (1991) Utilisation of the method of Kalman filtering for performing the on-line computation of background metabolism in the free-moving, free-feeding rat. Physiol Behav 49: 177–187.
[21]
Even PC, Mokhtarian A, Pele A (1994) Practical aspects of indirect calorimetry in laboratory animals. Neurosci Biobehav Rev 18: 435–447.
Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, et al. (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742–755.
[24]
Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, et al. (1999) 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-T？HCand related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905–2914.
[25]
Defer N, Wan J, Souktani R, Escoubet B, Perier M, et al. (2009) The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. Faseb J.
[26]
Pertwee R, Griffin G, Fernando S, Li X, Hill A, et al. (1995) AM630, a competitive cannabinoid receptor antagonist. Life Sci 56: 1949–1955.
[27]
Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602–26614.
[28]
Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494–1505.
[29]
Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, et al. (2006) Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 126: 177–187.
[30]
Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171–3180.
[31]
Miller AM, Stella N (2008) CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153: 299–308.
[32]
Montecucco F, Burger F, Mach F, Steffens S (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294: H1145–1155.
[33]
Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, et al. (2000) Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 275: 15621–15628.
[34]
Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA (2007) Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267: 63–69.
[35]
Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, et al. (2008) Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 16: 553–565.
[36]
Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F, Ripoll C, et al. (2006) Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39: 155–162.
[37]
Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115–124.
[38]
Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838–2843.
[39]
Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, et al. (2007) Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring) 15: 837–845.
[40]
Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053–3060.
[41]
Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 31: 692–699.
[42]
Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122–129.
[43]
Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, et al. (2008) Paracrine Activation of Hepatic CB(1) Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver. Cell Metab 7: 227–235.
[44]
Bellocchio L, Mancini G, Vicennati V, Pasquali R, Pagotto U (2006) Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol 6: 586–591.
[45]
Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, et al. (2005) Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C. Hepatology 42: 63–71.
[46]
Teixeira-Clerc F, Julien B, Grenard P, Tran-Van-Nhieu J, Deveaux V, et al. (2006) CB1 cannabinoid receptor antagonism: a novel strategy for the treatment of liver fibrosis. Nature Medicine 12: 671–676.
[47]
Hezode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, et al. (2008) Daily cannabis use, a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134: 432–439.
[48]
Mallat A, Lotersztajn S (2006) Endocannabinoids as novel mediators of liver diseases. Journal of Endocrinological Investigation 29: 58–65.
